Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).

Phase: N/A Priority: Normal
NCT ID: NCT04526977 Org: User:
Start: 01/10/21 End: 03/30/23 Due: 03/30/24

Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19.

Phase: N/A Priority: Normal
NCT ID: NCT04402827 Org: User:
Start: 08/01/20 End: 09/30/21 Due: 09/30/22

Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome

Phase: N/A Priority: Normal
NCT ID: NCT04403061 Org: User:
Start: 05/22/20 End: 01/10/21 Due: 01/10/22

Renal and Bone Outcome After Switching Tenofovir to Different Antiretroviral Strategies

Phase: N/A Priority: Normal
NCT ID: NCT02209740 Org: User:
Start: 07/31/14 End: 12/31/15 Due: 12/31/16

Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term

Phase: N/A Priority: Normal
NCT ID: NCT01060618 Org: User:
Start: 05/31/09 End: 12/31/11 Due: 12/31/12

Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT02116751 Org: User:
Start: 04/30/14 End: 12/31/14 Due: 12/31/15

Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances

Phase: N/A Priority: Normal
NCT ID: NCT02614027 Org: User:
Start: 02/29/16 End: 06/30/18 Due: 06/30/19

Bitherapy With the Combination of Raltegravir and Darunavir (BIRDi)

Phase: N/A Priority: Normal
NCT ID: NCT03348449 Org: User:
Start: 12/15/17 End: 06/29/18 Due: 06/29/19

Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression

Phase: N/A Priority: Normal
NCT ID: NCT02491242 Org: User:
Start: 11/30/15 End: 06/30/18 Due: 06/30/19